DIA会员及用户请点击登录

登录

忘记用户 ID? or 忘记密码?

Not a Member?

创建账户并加入。

Nihonbashi Life Science HUB

2018 年 10 月 25 日 9:00 上午 - 2018 年 10 月 26 日 6:00 下午

8F, 1-5-5 Nihonbashi-muromachi, Chuo-ku, Tokyo, 103-0022 Japan

7th DIA Cardiac Safety Workshop in Japan

It will be a unique opportunity to learn of and discuss the current state and future directions of CV risk assessments and how to prepare for a new regulatory paradigm.

[Session 6] Strategies to Assess, Prevent and Mitigate Cardiotoxicity

Session Chair(s)

Yuji  Kumagai, MD, PhD

Yuji Kumagai, MD, PhD

Professor, Kitasato Clinical Research Center

Kitasato University Hospital, Japan

Boaz  Mendzelevski, MD

Boaz Mendzelevski, MD

Consultant Cardiologist

Cardiac Safety Consultants Ltd., United Kingdom

Speaker(s)

Boaz  Mendzelevski, MD

Cardiovascular Safety Assessments of Oncology Drugs in Clinical Development

Boaz Mendzelevski, MD

Cardiac Safety Consultants Ltd., United Kingdom

Consultant Cardiologist

Manabu  Minaimi, MD, PhD

Important Adverse Effects of Molecular-Targeting Drugs in Aspects of Cardio-Oncology

Manabu Minaimi, MD, PhD

Kyoto University Hospital, Japan

Institute for Advancement of Clinical and Translational Science (iACT)

Wataru  Shioyama, MD, PhD

TKI Induced Cardiotoxicity and Drug-Induced Thrombosis

Wataru Shioyama, MD, PhD

Osaka International Cancer Institute, Japan

Deputy Manager, Department of Cardiovascular Medicine, Onco-Cardiology Unit

Krishna  Prasad, DrMed, MD, MRCP, FRCP

Oncology Drug-Induced Cardiotoxicity: Strategies to Assess, Prevent and Mitigate Cardiotoxicity Pre- and Post-Approval

Krishna Prasad, DrMed, MD, MRCP, FRCP

Medicines and Healthcare Products Regulatory Agency (MHRA), United Kingdom

Deputy Director, Innovative Medicines, HQA/Licensing

Hitoshi  Kanno, MD, PhD

Cardio-Oncology from the Regulator’s Perspective

Hitoshi Kanno, MD, PhD

Pharmaceuticals and Medical Devices Agency (PMDA), Japan

Reviewer, Office of New Drug V

获得信息并保持参与

不要错失任何机会——请加入我们的邮件列表,了解DIA的观点和事件。